S1 Table. Solver run times and percent changes in final diseased neuron concentration and Aβ42 load.
Each percent change is given in absolute value when compared to results from a run solved with ode45 for a 90 day simulation of a nine month-old APP/PS1 transgenic mouse with mg ⋅ kg−1 bexarotene treatment.
S2 Table. Percent change of the concentration of healthy brain cells in a 90 day simulation of nine-month-old APP/PS1 mouse with 100 mg ⋅ kg−1 bexarotene treatment.
Parameters are increased by 10%, and the approximate corresponding percent change of the system is given for 0 mg ⋅ kg−1 and 100 mg ⋅ kg−1 of bexarotene.
Citation: Rosenthal J, Belfort G, Isaacson D (2016) Correction: Early Treatment Critical: Bexarotene Reduces Amyloid-Beta Burden In Silico. PLoS ONE 11(5): e0156474. https://doi.org/10.1371/journal.pone.0156474
Published: May 24, 2016
Copyright: © 2016 Rosenthal et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.